Mohamed Gamil

453 total citations
24 papers, 255 citations indexed

About

Mohamed Gamil is a scholar working on Epidemiology, Hepatology and Surgery. According to data from OpenAlex, Mohamed Gamil has authored 24 papers receiving a total of 255 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Epidemiology, 15 papers in Hepatology and 3 papers in Surgery. Recurrent topics in Mohamed Gamil's work include Hepatitis C virus research (14 papers), Liver Disease Diagnosis and Treatment (12 papers) and Hepatitis B Virus Studies (8 papers). Mohamed Gamil is often cited by papers focused on Hepatitis C virus research (14 papers), Liver Disease Diagnosis and Treatment (12 papers) and Hepatitis B Virus Studies (8 papers). Mohamed Gamil collaborates with scholars based in Belgium, Egypt and United States. Mohamed Gamil's co-authors include Anne Fanning, Gamal Esmat, Maissa El Raziky, Mohamed Hassany, Mohamed El‐Kassas, Frederik Nevens, Wim Laleman, W. Van Steenbergen, Raymond Aerts and Bruno Desschans and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Journal of Hepatology.

In The Last Decade

Mohamed Gamil

23 papers receiving 246 citations

Peers

Countries citing papers authored by Mohamed Gamil

Since Specialization

Citations

This map shows the geographic impact of Mohamed Gamil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohamed Gamil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohamed Gamil more than expected).

Fields of papers citing papers by Mohamed Gamil

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohamed Gamil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohamed Gamil. The network helps show where Mohamed Gamil may publish in the future.

Co-authorship network of co-authors of Mohamed Gamil

This figure shows the co-authorship network connecting the top 25 collaborators of Mohamed Gamil. A scholar is included among the top collaborators of Mohamed Gamil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohamed Gamil. Mohamed Gamil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial. 2024 ·Journal of Clinical Oncology ·Natasha B. Leighl, Hiroaki Akamatsu, (unknown), Ying Cheng, Anna Minchom, Melina E. Marmarelis, Rachel E. Sanborn, James Chih‐Hsin Yang, Baogang Liu, Thomas John, Bartomeu Massutí, Alexander I. Spira, (unknown), (unknown), Ali Alhadab, Remy B. Verheijen, Mohamed Gamil, Joshua Bauml, Mahadi Baig, Antonio Passaro	12
2	CROCuS, a Phase II Study Evaluating the Antiviral Activity, Clinical Outcomes, and Safety of Rilematovir in Children Aged ≥ 28 Days and ≤ 3 Years with Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus 2024 ·Pediatric Drugs ·Fernando Ferrero, Chien‐Yu Lin, Johannes G. Liese, Kléber Giovanni Luz, (unknown), (unknown), Manuel Gijón, Cristina Calvo, (unknown), Teck‐Hock Toh, (unknown), (unknown), Sarah Rusch, (unknown), (unknown), Leen Vijgen, Dymphy Huntjens, (unknown), (unknown), Mohamed Gamil, Marita Stevens, (unknown)	6
3	A long-term study of liver-related events in Caucasian hepatitis B patients with normal ALT values and high viremia 2022 ·Acta Gastro Enterologica Belgica ·Özgür M. Koc, Jef Verbeek, Ger H. Koek, Rob Bielen, Dana Busschots, Mohamed Gamil, Geert Robaeys, Frederik Nevens	3
4	Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus‐infected patients: Long‐term follow‐up results from the open‐label, Phase II IMPACT study 2020 ·Health Science Reports ·Eric Lawitz, Fred Poordad, Julio Gutiérrez, Maria Beumont, Greet Beets, (unknown), P. Van Remoortere, Donghan Luo, Leen Vijgen, Veerle Van Eygen, Mohamed Gamil	5
5	The Role of Intra-Operative Mobile Gamma Camera and Gamma Probe in Detection of Sentinel Lymph Node in Early Stage Breast Cancer 2019 ·(unknown), Mohamed Gamil, (unknown), (unknown), (unknown), (unknown)	3
6	Novel scores combining AFP with non‐invasive markers for prediction of liver fibrosis in chronic hepatitis C patients 2018 ·Journal of Medical Virology ·Mohamed Gamil, Mohamed Alboraie, (unknown), Aisha Elsharkawy, Noha Asem, Tamer Elbaz, (unknown), (unknown), (unknown), Gamal Esmat	23
7	A164 RAPID INTRAHEPATIC AND PERIPHERAL BLOOD HCV RNA DECLINE AND HCV-SPECIFIC IMMUNE RESPONSE INCREASE DURING IFN-FREE DAA THERAPY IN HCV TREATMENT-NAÏVE PATIENTS 2018 ·Journal of the Canadian Association of Gastroenterology ·Sonya A. MacParland, Vera Cherepanov, Leen Vijgen, Mohamed Gamil, Maria Beumont, (unknown), (unknown), (unknown), Mario Ostrowski, Mayur Brahmania, David Wong, Richard Harrigan, Harry L.A. Janssen, Mark Sulkowski, Jordan J. Feld	1
8	Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection with or without Cirrhosis Treated with Interferon-Free, Simeprevir-Containing Regimens: Results from Four Phase II/III Studies 2017 ·Gastroenterology ·(unknown), Eric Lawitz, Paul Y. Kwo, Mark Sulkowski, Mohamed Gamil, Chris Corbett, Donghan Luo, Jane Scott	1
9	Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection 2017 ·Journal of Viral Hepatitis ·Mark Sulkowski, Jordan J. Feld, Eric Lawitz, Franco Felizarta, (unknown), (unknown), Reem Ghalib, William B. Smith, Veerle Van Eygen, (unknown), Leen Vijgen, Mohamed Gamil, Thomas N. Kakuda, Sivi Ouwerkerk‐Mahadevan, P. Van Remoortere, Maria Beumont	8
10	Simeprevir plus sofosbuvir for eight or 12 weeks in treatment‐naïve and treatment‐experienced hepatitis C virus genotype 4 patients with or without cirrhosis 2016 ·Journal of Viral Hepatitis ·Maissa El Raziky, Mohamed Gamil, (unknown), (unknown), Wahid Doss, (unknown), (unknown), Ralph DeMasi, Sofia Keim, Isabelle Lonjon‐Domanec, (unknown), (unknown), Mohamed Hassany, Imam Waked	25
11	P1346 : Study protocol for a partly randomised, open-label phase IIA trial of once-daily simeprevir combined with sofosbuvir for the treatment of HCV genotype 4 infected patients with or without cirrhosis (OSIRIS) 2015 ·Journal of Hepatology ·Maissa El Raziky, Mohamed Gamil, (unknown), (unknown), Mohamed Hassany, Marwa Khairy, (unknown), Ahmed Gomaa, Samuel M. Keim, (unknown), Ralph DeMasi, Isabelle Lonjon‐Domanec, Wahid Doss, Imam Waked	1
12	Pelvic exenteration and composite sacral resection in the surgical treatment of locally recurrent rectal cancer 2014 ·Journal of the Egyptian National Cancer Institute ·(unknown), Medhat Khafagy, Mohamed Gamil, (unknown), (unknown), Nadia Mokhtar, Mohamed Lotayef, (unknown)	4
13	SHOULD CHRONIC HEPATITIS B BE TREATED AS EARLY AS POSSIBLE? 2013 ·International Journal of Technology Assessment in Health Care ·Frank Hulstaert, Christoph Schwierz, Frederik Nevens, Nancy Thiry, Mohamed Gamil, Isabelle Colle, (unknown), Yves Horsmans	6
14	How to optimize HCV therapy in genotype 4 patients 2013 ·Liver International ·Gamal Esmat, Mohamed El‐Kassas, Mohamed Hassany, Mohamed Gamil, Maissa El Raziky	12
15	A Road Map For Integrating a Giant Field: Case Study 2013 ·North Africa Technical Conference and Exhibition ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Mohamed Gamil, (unknown)	10
16	Risk Factors for Bleeding and Clinical Implications in Patients Undergoing Liver Transplantation 2012 ·Transplantation Proceedings ·Mohamed Gamil, Jacques Pirenne, Hannah van Malenstein, Marleen Verhaegen, Bruno Desschans, Diethard Monbaliu, Raymond Aerts, Wim Laleman, David Cassiman, Chris Verslype, W. Van Steenbergen, Jos van Pelt, Frederik Nevens	36
17	Evaluation économique du traitement antiviral de l’hépatite B chronique en Belgique 2011 ·Christoph Schwierz, Nancy Thiry, (unknown), Mohamed Gamil, Frederik Nevens, Isabelle Colle, Yves Horsmans, Frank Hulstaert	0
18	The future for the treatment of genotype 4 chronic hepatitisC 2011 ·Liver International ·Gamal Esmat, Maissa El Raziky, Mohamed El‐Kassas, Mohamed Hassany, Mohamed Gamil	21
19	The first 24 hours after surgery 1991 ·Anaesthesia ·Mohamed Gamil, Anne Fanning	34
20	SERIAL PEAK EXPIRATORY FLOW RATES IN MOTHERS DURING CAESAREAN SECTION UNDER EXTRADURAL ANAESTHESIA 1989 ·British Journal of Anaesthesia ·Mohamed Gamil	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact